Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MarketLine (a Datamonitor Company)
$175.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biomarin Pharmaceutical Inc announces FDA approval for VIMIZIM


Friday, 14 Feb 2014 04:30pm EST 

Biomarin Pharmaceutical Inc:Says the U.S. Food and Drug Administration has approved VIMIZIM for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). 

Related Company News

Company Quote

70.04
0.96 +1.39%
12:07pm EDT